138 related articles for article (PubMed ID: 36319070)
1. In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human.
Alsmadi MM; Alzughoul SB
Biopharm Drug Dispos; 2023 Jun; 44(3):221-244. PubMed ID: 36319070
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.
Yuan R; Venitz J
Int J Clin Pharmacol Ther; 2000 May; 38(5):245-53. PubMed ID: 10839468
[TBL] [Abstract][Full Text] [Related]
3. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.
Sayama H; Takubo H; Komura H; Kogayu M; Iwaki M
AAPS J; 2014 Sep; 16(5):1018-28. PubMed ID: 24912798
[TBL] [Abstract][Full Text] [Related]
4. Effect of Chronic Kidney Disease on Hepatic Clearance of Drugs in Rats.
Tokunaga A; Miyamoto H; Fumoto S; Nishida K
Biol Pharm Bull; 2020; 43(9):1324-1330. PubMed ID: 32879206
[TBL] [Abstract][Full Text] [Related]
5. Uremic Toxins and Protein-Bound Therapeutics in AKI and CKD: Up-to-Date Evidence.
Chen JH; Chiang CK
Toxins (Basel); 2021 Dec; 14(1):. PubMed ID: 35050985
[TBL] [Abstract][Full Text] [Related]
6. PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.
Hsueh CH; Hsu V; Zhao P; Zhang L; Giacomini KM; Huang SM
Clin Pharmacol Ther; 2018 Mar; 103(3):485-492. PubMed ID: 28738449
[TBL] [Abstract][Full Text] [Related]
7. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin.
Butrovich MA; Tang W; Boulton DW; Nolin TD; Sharma P
J Clin Pharmacol; 2022 Aug; 62(8):1018-1029. PubMed ID: 35247279
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of salivary markers of kidney functions in acute and chronic kidney diseases.
Kovalčíková AG; Pavlov K; Lipták R; Hladová M; Renczés E; Boor P; Podracká Ľ; Šebeková K; Hodosy J; Tóthová Ľ; Celec P
Sci Rep; 2020 Dec; 10(1):21260. PubMed ID: 33277585
[TBL] [Abstract][Full Text] [Related]
9. Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption.
Huang W; Isoherranen N
CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):571-583. PubMed ID: 32977369
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases.
Liu B; Luo F; Luo X; Duan S; Gong Z; Peng J
Curr Drug Metab; 2018; 19(7):568-576. PubMed ID: 29299983
[TBL] [Abstract][Full Text] [Related]
12. A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease.
Malik PRV; Yeung CHT; Ismaeil S; Advani U; Djie S; Edginton AN
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S52-S62. PubMed ID: 33205424
[TBL] [Abstract][Full Text] [Related]
13. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
Hu MC; Shi M; Gillings N; Flores B; Takahashi M; Kuro-O M; Moe OW
Kidney Int; 2017 May; 91(5):1104-1114. PubMed ID: 28131398
[TBL] [Abstract][Full Text] [Related]
14. In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease.
Su M; Liu X; Zhao Y; Zhu Y; Wu M; Liu K; Yang G; Liu W; Wang L
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202741
[TBL] [Abstract][Full Text] [Related]
15. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
[TBL] [Abstract][Full Text] [Related]
16. Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives.
Srinivas NR
Arzneimittelforschung; 2010; 60(12):731-48. PubMed ID: 21265465
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Translation of Microfluidic Transporter
van der Made TK; Fedecostante M; Scotcher D; Rostami-Hodjegan A; Sastre Toraño J; Middel I; Koster AS; Gerritsen KG; Jankowski V; Jankowski J; Hoenderop JGJ; Masereeuw R; Galetin A
Mol Pharm; 2019 Nov; 16(11):4551-4562. PubMed ID: 31525064
[TBL] [Abstract][Full Text] [Related]
18. Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure.
Lee YH; Lee MH; Shim CK
Pharm Res; 1992 Dec; 9(12):1599-606. PubMed ID: 1488404
[TBL] [Abstract][Full Text] [Related]
19. Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.
Vilay AM; Churchwell MD; Mueller BA
Crit Care; 2008; 12(6):235. PubMed ID: 19040780
[TBL] [Abstract][Full Text] [Related]
20. Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease.
Tan SPF; Willemin ME; Snoeys J; Shen H; Rostami-Hodjegan A; Scotcher D; Galetin A
Clin Pharmacol Ther; 2023 Dec; 114(6):1243-1253. PubMed ID: 37620246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
